Opendata, web and dolomites

Tbet ILC JFN

The role of innate lymphoid cells in regulating intestinal inflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Tbet ILC JFN" data sheet

The following table provides information about the project.

Coordinator
KING'S COLLEGE LONDON 

Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS
website: www.kcl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://kclpure.kcl.ac.uk/portal/joana.pereira_das_neves.html
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2017-10-08

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 183˙454.00

Map

 Project objective

The maintenance of intestinal homeostasis has local and systemic implications for the host health and depends on a balance regulated by interactions between the immune system and the gut microbiota. Recently, it has become clear that a newly identified group of cells, innate lymphoid cells (ILCs), have a crucial role in intestinal homeostasis and host defence. ILCs respond rapidly to changes in the gut microenvironment and produce several cytokines that regulate intestinal inflammation. Although the pathways responsible for ILCs’ development and differentiation are only starting to be elucidated, the transcription factor T-bet has emerged as a key regulator of these processes. This proposal aims to clarify the molecular mechanisms involved in the T-bet-dependent development and function of ILCs and how these processes can be modulated by the intestinal microbiota. First, we propose to use a novel lineage-tracing mouse model that uses dual fluorescence reporters to differentiate between cells that currently express T-bet from cells that used to express T-bet, in order to distinguish between the mechanisms responsible for ILCs development from the mechanisms involved in ILCs function. In addition, we aim to uncover novel T-bet associated pathways that are active on intestinal ILCs, and understand how these pathways are regulated by the gut microbiome. Moreover, we aim to develop a novel in vitro co-culture system of ILCs in intestinal organoids, which will facilitate our studies and benefit future studies investigating the development and functions of intestinal lymphocytes. The detailed study of ILCs development, differentiation and function and the identification of novel T-bet and microbiota associated pathways will open new possibilities in the modulation of ILC’s functions and inform on how to divert these cells away from their pathogenic phenotypes that are responsible for gut inflammation and could have a significant impact on the field of intestinal immunity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TBET ILC JFN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TBET ILC JFN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More